Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study.

We examined the relation between the use of hormone replacement therapy (HRT) and the incidence of central nervous system (CNS) tumours in a large prospective study of 1,147,894 postmenopausal women. Women were aged 56.6 years on average at entry, and HRT use was recorded at recruitment and updated,...

Full description

Bibliographic Details
Main Authors: Benson, V, Pirie, K, Green, J, Bull, D, Casabonne, D, Reeves, G, Beral, V
Format: Journal article
Language:English
Published: 2010
_version_ 1797081209951485952
author Benson, V
Pirie, K
Green, J
Bull, D
Casabonne, D
Reeves, G
Beral, V
author_facet Benson, V
Pirie, K
Green, J
Bull, D
Casabonne, D
Reeves, G
Beral, V
author_sort Benson, V
collection OXFORD
description We examined the relation between the use of hormone replacement therapy (HRT) and the incidence of central nervous system (CNS) tumours in a large prospective study of 1,147,894 postmenopausal women. Women were aged 56.6 years on average at entry, and HRT use was recorded at recruitment and updated, where possible, about 3 years later. During a mean follow-up of 5.3 years per woman, 1,266 CNS tumours were diagnosed, including 557 gliomas, 311 meningiomas and 117 acoustic neuromas. Compared with never users of HRT, the relative risks (RRs) for all incident CNS tumours, gliomas, meningiomas and acoustic neuromas in current users of HRT were 1.20 (95% CI: 1.05-1.36), 1.09 (95% CI: 0.89-1.32), 1.34 (95% CI: 1.03-1.75) and 1.58 (95% CI: 1.02-2.45), respectively, and there was no significant difference in the relative risks by tumour type (heterogeneity p = 0.2). In past users of HRT the relative risk was 1.07 (95% CI: 0.93-1.24) for all CNS tumours. Among current users of HRT, there was significant heterogeneity by the type of HRT with the users of oestrogen-only HRT at higher risk of all CNS tumours than users of oestrogen-progestagen HRT (RR = 1.42, 95% CI: 1.21-1.67 versus RR = 0.97, 95% CI: 0.82-1.16) (heterogeneity p < 0.001). Among current users of oestrogen-only and oestrogen-progestagen HRT, there was no significant heterogeneity by duration of use, hormonal constituent or mode of administration of HRT.
first_indexed 2024-03-07T01:11:21Z
format Journal article
id oxford-uuid:8d1d3c32-25af-4398-9e00-65a83d2de8b0
institution University of Oxford
language English
last_indexed 2024-03-07T01:11:21Z
publishDate 2010
record_format dspace
spelling oxford-uuid:8d1d3c32-25af-4398-9e00-65a83d2de8b02022-03-26T22:49:11ZHormone replacement therapy and incidence of central nervous system tumours in the Million Women Study.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8d1d3c32-25af-4398-9e00-65a83d2de8b0EnglishSymplectic Elements at Oxford2010Benson, VPirie, KGreen, JBull, DCasabonne, DReeves, GBeral, VWe examined the relation between the use of hormone replacement therapy (HRT) and the incidence of central nervous system (CNS) tumours in a large prospective study of 1,147,894 postmenopausal women. Women were aged 56.6 years on average at entry, and HRT use was recorded at recruitment and updated, where possible, about 3 years later. During a mean follow-up of 5.3 years per woman, 1,266 CNS tumours were diagnosed, including 557 gliomas, 311 meningiomas and 117 acoustic neuromas. Compared with never users of HRT, the relative risks (RRs) for all incident CNS tumours, gliomas, meningiomas and acoustic neuromas in current users of HRT were 1.20 (95% CI: 1.05-1.36), 1.09 (95% CI: 0.89-1.32), 1.34 (95% CI: 1.03-1.75) and 1.58 (95% CI: 1.02-2.45), respectively, and there was no significant difference in the relative risks by tumour type (heterogeneity p = 0.2). In past users of HRT the relative risk was 1.07 (95% CI: 0.93-1.24) for all CNS tumours. Among current users of HRT, there was significant heterogeneity by the type of HRT with the users of oestrogen-only HRT at higher risk of all CNS tumours than users of oestrogen-progestagen HRT (RR = 1.42, 95% CI: 1.21-1.67 versus RR = 0.97, 95% CI: 0.82-1.16) (heterogeneity p < 0.001). Among current users of oestrogen-only and oestrogen-progestagen HRT, there was no significant heterogeneity by duration of use, hormonal constituent or mode of administration of HRT.
spellingShingle Benson, V
Pirie, K
Green, J
Bull, D
Casabonne, D
Reeves, G
Beral, V
Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study.
title Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study.
title_full Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study.
title_fullStr Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study.
title_full_unstemmed Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study.
title_short Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study.
title_sort hormone replacement therapy and incidence of central nervous system tumours in the million women study
work_keys_str_mv AT bensonv hormonereplacementtherapyandincidenceofcentralnervoussystemtumoursinthemillionwomenstudy
AT piriek hormonereplacementtherapyandincidenceofcentralnervoussystemtumoursinthemillionwomenstudy
AT greenj hormonereplacementtherapyandincidenceofcentralnervoussystemtumoursinthemillionwomenstudy
AT bulld hormonereplacementtherapyandincidenceofcentralnervoussystemtumoursinthemillionwomenstudy
AT casabonned hormonereplacementtherapyandincidenceofcentralnervoussystemtumoursinthemillionwomenstudy
AT reevesg hormonereplacementtherapyandincidenceofcentralnervoussystemtumoursinthemillionwomenstudy
AT beralv hormonereplacementtherapyandincidenceofcentralnervoussystemtumoursinthemillionwomenstudy